CUBE vs JAZZ · P/E 25, rev $1.07B vs P/E 1988, rev $4.07B
CubeSmart (CUBE) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the CUBE and JAZZ stock pages for the full models.
Not investment advice.